Terns Pharmaceuticals Inc is a biotechnology business based in the US. Terns Pharmaceuticals shares (TERN) are listed on the NASDAQ and all prices are listed in US Dollars. Terns Pharmaceuticals employs 30 staff and has a market cap (total outstanding shares value) of 0.00.
Our top pick for
Beginners
Our top pick for
Guided Investing
Our top pick for
Experienced Investors
| Latest market close | $9.94 |
|---|---|
| 52-week range | $6.92 - $28.36 |
| 50-day moving average | $11.29 |
| 200-day moving average | $13.82 |
| Wall St. target price | $20.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-3.39 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $9.94 from 2021-10-14
| 1 week (2021-10-08) | -3.59% |
|---|---|
| 1 month (2021-09-15) | -7.19% |
| 3 months (2021-07-15) | 12.44% |
| 6 months (2021-04-15) | -43.87% |
| 1 year (2020-10-11) | N/A |
|---|---|
| 2 years (2019-10-11) | N/A |
| 3 years (2018-10-11) | N/A |
| 5 years (2016-10-11) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -39.83% |
| Return on equity TTM | -68.73% |
| Profit margin | 0% |
| Book value | $7.22 |
| Market capitalisation | $259.1 million |
TTM: trailing 12 months
There are currently 688,997 Terns Pharmaceuticals shares held short by investors – that's known as Terns Pharmaceuticals's "short interest". This figure is 2.4% up from 672,985 last month.
There are a few different ways that this level of interest in shorting Terns Pharmaceuticals shares can be evaluated.
Terns Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Terns Pharmaceuticals shares currently shorted divided by the average quantity of Terns Pharmaceuticals shares traded daily (recently around 64033.178438662). Terns Pharmaceuticals's SIR currently stands at 10.76. In other words for every 100,000 Terns Pharmaceuticals shares traded daily on the market, roughly 10760 shares are currently held short.
To gain some more context, you can compare Terns Pharmaceuticals's short interest ratio against those of similar companies.
However Terns Pharmaceuticals's short interest can also be evaluated against the total number of Terns Pharmaceuticals shares, or, against the total number of tradable Terns Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Terns Pharmaceuticals's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Terns Pharmaceuticals shares in existence, roughly 30 shares are currently held short) or 0.07% of the tradable shares (for every 100,000 tradable Terns Pharmaceuticals shares, roughly 70 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Terns Pharmaceuticals.
Find out more about how you can short Terns Pharmaceuticals stock.
We're not expecting Terns Pharmaceuticals to pay a dividend over the next 12 months.
Terns Pharmaceuticals's shares were split on a 1000:50 basis on 3 November 2013. So if you had owned 50 shares the day before before the split, the next day you'd have owned 1000 shares. This wouldn't directly have changed the overall worth of your Terns Pharmaceuticals shares – just the quantity. However, indirectly, the new 95% lower share price could have impacted the market appetite for Terns Pharmaceuticals shares which in turn could have impacted Terns Pharmaceuticals's share price.
Terns Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and other chronic liver diseases. It develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase I clinical trial for the treatment of NASH. The company also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and GLP-1R, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to address metabolic processes involved in the pathogenesis of NASH. Terns Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Foster City, California. .
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.